A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Public ClinicalTrials.gov record NCT03329950. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Study identification
- NCT ID
- NCT03329950
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Celldex Therapeutics
- Industry
- Enrollment
- 132 participants
Conditions and interventions
Conditions
- Bladder Urothelial Carcinoma
- Breast Cancer
- Cholangiocarcinoma
- Colorectal Cancer
- Diffuse Large B-cell Lymphoma (DLBCL)
- Esophageal Cancer
- Fallopian Tube Cancer
- Follicular Lymphoma
- Gastric Cancer
- Head and Neck Cancer
- Hepatic Cancer
- Indolent B-cell Lymphomas
- Lymphoplasmacytic Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Melanoma
- Mucosa Associated Lymphoid Tissue
- Non-Hodgkin Lymphoma
- Non-small Cell Lung Cancer
- Other Solid Tumors
- Ovarian Cancer
- Pancreatic Adenocarcinoma
- Primary Peritoneal Cancer
- Renal Cell Carcinoma
- Small Lymphocytic Leukemia
- Waldenstrom's Disease
Interventions
- CDX-1140 Drug
- CDX-301 Drug
- Chemotherapy Drug
- pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2017
- Primary completion
- Sep 12, 2022
- Completion
- Sep 12, 2022
- Last update posted
- Mar 27, 2024
2017 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Insititute | Scottsdale | Arizona | 85258 | — |
| Northside Hospital, Inc. | Atlanta | Georgia | 30342 | — |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Gabrail Cancer Center Research LLC | Canton | Ohio | 44718 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Abramson Cancer Center at the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Rhode Island Hospital (RIH) The Miriam Hospital (TMH) | Providence | Rhode Island | 02903 | — |
| Houston Methodist | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03329950, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2024 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03329950 live on ClinicalTrials.gov.